Pushing boundaries in idiopathic pulmonary fibrosis clinical research
Explore the evolving idiopathic pulmonary fibrosis (IPf) treatment landscape.
EMA guideline on computerised systems and electronic data in clinical trials
Key considerations on the impact of the new framework of globally applicable standards.
Exploring partnership culture and its impact on outsourcing and operational strategy
Actionable insights, proven strategies, and expert recommendations.
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
Early Clinical and Bioanalytical Solutions
Innovative early clinical solutions that will advance your drug development strategy.
Expert medical imaging solutions for all stages of clinical research enabling improved decision making, increased efficiency and reduced trial costs.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data.
Expertise in mission-critical pricing, market access, and reimbursement.
ICON is the world's largest provider of FSP services.
AI and adverse event literature detection for post-market surveillance
21 February 2024. Register now.
The future of pharmacovigilance: Exploring automation and AI in literature surveillance
22 February 2024. Register today.
Navigating the complexity of real-world healthcare data: choosing the right tools at the right time
22 March 2024. Register now.
Practical guidance for successful global regulatory submissions: Understanding FDA and PMDA data standards requirements
26 March 2024. Register now.